Drug Approval | February 17, 2022
USFDA approves Lupin’s Supplemental New Drug Application for Solosec
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
